Vistagen Therapeutics (VTGN) PT Lowered to $22.00

Vistagen Therapeutics (NASDAQ:VTGN) had its target price decreased by equities researchers at Chardan Capital from $30.00 to $22.00 in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock.

Vistagen Therapeutics (VTGN) opened at $1.16 on Thursday. Vistagen Therapeutics has a 1 year low of $0.69 and a 1 year high of $3.15. The firm has a market cap of $26.00, a PE ratio of -0.79 and a beta of -1.31. The company has a debt-to-equity ratio of -0.01, a current ratio of 1.23 and a quick ratio of 1.23.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings results on Thursday, November 9th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($0.05). equities analysts expect that Vistagen Therapeutics will post -1.99 earnings per share for the current year.

An institutional investor recently raised its position in Vistagen Therapeutics stock. Sphera Funds Management LTD. grew its position in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) by 94.5% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,058,386 shares of the company’s stock after buying an additional 514,286 shares during the quarter. Sphera Funds Management LTD. owned 9.08% of Vistagen Therapeutics worth $1,693,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 8.02% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at

Vistagen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply